Skip to main content

Advertisement

Table 3 Applications of adjuvant treatment with interferon in IFN group

From: A meta-analysis and systematic review: adjuvant interferon therapy for patients with viral hepatitis-related hepatocellular carcinoma

Study Intervention Follow-up (months)
Ikeda K (2000) 10 patients received natural IFN-β 6×106 twice a week for 36 months 25.0
Kubo S (2000) 15 patients received 6×106 IFN-α intramuscularly every day for 2 weeks, then three times weekly for 14 weeks, and finally twice weekly for 88 weeks. 60.0
Shiratori Y (2003) 49 patients received 6×106 IFN-α intramuscularly three times weekly for 48 weeks. 85.2
Lin SM (2004) 20 patients received 3×106 IFN-α 2b intramuscularly three times weekly for 24 months. 27.0
Piao CY (2005) 30 patients orally received 100 mg of lamivudine daily after HCC treatment. 24.0
Mazzaferro V (2006) 76 patients received 3×106 IFN-α 2b three times weekly for 48 weeks. 45.0
Sun HC (2006) 118 patients received 3×106 IFN-α intramuscularly twice a week for 2 weeks and then 5×106 three times weekly for 18 months. 36.5
Lo CM (2007) 40 patients received 10×106/m2 IFN-α 2b subcutaneously three times weekly for 16 weeks. 30.0
Li M (2009) 108 patients received IFN-α 2b 3×106 three times weekly by intramuscular injection one week. 24.8
Li N (2010) 43 patients received lamivudine with or without adefovir dipivoxil. 24.0
Ishikawa (2012) 29 patients received PEG-IFN α-2b/ribavirin after curative HCC treatment. 36.0